The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high estimate of $82.00, and a low estimate of $68.00. A negative shift in sentiment is ...

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral. Analyst Price Forecast Suggests 68.61% Upside As of May 7, 2025, the average ...

On Tuesday, BTIG analyst Ryan Zimmerman downgraded Globus Medical shares (NYSE:GMED) from Buy to Neutral, citing concerns following the company’s first-quarter results for 2025. According to ...

Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Globus Medical, Inc. has a 1 year low of $54.48 and a 1 year high of $94.93. The firm has a 50 day moving average price of $69.35 and a 200 day moving average price of $78.83.

Globus Medical’s first quarter of 2025 proved challenging, with results falling below expectations. The company attributed this underperformance to delays in Enabling Technology deals ...

Across the recent three months, 4 analysts have shared their insights on Globus Medical (NYSE:GMED), expressing a variety of opinions spanning from bullish to bearish. In the table below ...